Egis Pharmaceuticals Ltd. expands its portfolio with a well-known product line

Egis has already been distributing topical skin-applicable products, and with the current acquisition, the company aims to expand this portfolio with additional products.

“We are bringing the production of the leading drug of the newly acquired product line back to Hungary, and following the successful technology transfer, we will continue to manufacture it in Egis’ new galenic plant in Körmend, which was handed over a few years ago,”

– added Csaba Poroszlai, CEO of Egis, to the announcement.

Egis Pharmaceuticals Ltd. is a pharmaceutical company with a history of more than 110 years, headquartered in Hungary and with active ingredient and pharmaceutical manufacturing plants. Its activities cover all value-creating processes in the pharmaceutical industry, from research and development to the production of active ingredients and finished products to sales.

Following its global business strategy, Teva Pharmaceuticals Ltd. has decided to divest itself of this product line and focus on its other global, topical brands for use on the skin.